ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million Read more
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology Read more
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors Read more
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager Read more
Calliditas Therapeutics announces full FDA approval of TARPEYO, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function Read more
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results Read more
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults Read more
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program Read more